Journal
JOURNAL OF CELL SCIENCE
Volume 125, Issue 5, Pages 1259-1273Publisher
COMPANY OF BIOLOGISTS LTD
DOI: 10.1242/jcs.095299
Keywords
-
Categories
Funding
- National Institutes of Health [RO1-CA136690, PO1-HL60231, RO1-CA116019, RO1-HL078564, RO1-GM60514]
- Leukemia and Lymphoma Society [5566-07]
- American Heart Association [SDG2280008, SDG3420042]
- National Cancer Institute [T32 CA108462]
- American Federation for Aging Research [A112457]
Ask authors/readers for more resources
In cancer progression, carcinoma cells gain invasive behavior through a loss of epithelial characteristics and acquisition of mesenchymal properties, a process that can lead to epithelial-mesenchymal transition (EMT). TGF-beta is a potent inducer of EMT, and increased TGF-beta signaling in cancer cells is thought to drive cancer-associated EMT. Here, we examine the physiological requirement for mTOR complex 2 (mTORC2) in cells undergoing EMT. TGF-beta rapidly induces mTORC2 kinase activity in cells undergoing EMT, and controls epithelial cell progression through EMT. By regulating EMT-associated cytoskeletal changes and gene expression, mTORC2 is required for cell migration and invasion. Furthermore, inactivation of mTORC2 prevents cancer cell dissemination in vivo. Our results suggest that the mTORC2 pathway is an essential downstream branch of TGF-beta signaling, and represents a responsive target to inhibit EMT and prevent cancer cell invasion and metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available